GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (STU:34LA) » Definitions » Quick Ratio

Alpine Immune Sciences (STU:34LA) Quick Ratio : 7.86 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Alpine Immune Sciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Alpine Immune Sciences's quick ratio for the quarter that ended in Dec. 2023 was 7.86.

Alpine Immune Sciences has a quick ratio of 7.86. It generally indicates good short-term financial strength.

The historical rank and industry rank for Alpine Immune Sciences's Quick Ratio or its related term are showing as below:

STU:34LA' s Quick Ratio Range Over the Past 10 Years
Min: 2.6   Med: 7.23   Max: 43.56
Current: 7.86

During the past 12 years, Alpine Immune Sciences's highest Quick Ratio was 43.56. The lowest was 2.60. And the median was 7.23.

STU:34LA's Quick Ratio is ranked better than
75.69% of 1555 companies
in the Biotechnology industry
Industry Median: 3.49 vs STU:34LA: 7.86

Alpine Immune Sciences Quick Ratio Historical Data

The historical data trend for Alpine Immune Sciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences Quick Ratio Chart

Alpine Immune Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.87 2.60 2.75 4.16 7.86

Alpine Immune Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.16 3.48 3.88 3.81 7.86

Competitive Comparison of Alpine Immune Sciences's Quick Ratio

For the Biotechnology subindustry, Alpine Immune Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpine Immune Sciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's Quick Ratio falls into.



Alpine Immune Sciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Alpine Immune Sciences's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(302.641-0)/38.496
=7.86

Alpine Immune Sciences's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(302.641-0)/38.496
=7.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpine Immune Sciences  (STU:34LA) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Alpine Immune Sciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpine Immune Sciences (STU:34LA) Business Description

Traded in Other Exchanges
Address
188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (STU:34LA) Headlines

No Headlines